Foghorn Therapeutics Highlights Chromatin Biology Leadership

Foghorn Therapeutics presented its strategic position as a leader in chromatin biology, emphasizing its Gene Traffic Control Platform® for developing precision therapeutics. The company highlighted its focus on drugging challenging targets implicated in up to 50% of all tumors, aiming for first-in-class and best-in-class approaches. This update underscores Foghorn's potential in unlocking multi-billion dollar opportunities through selective target engagement and its ongoing strategic partnership with Lilly, including a Phase 1 trial for FHD-909.